Literature DB >> 12633529

The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.

R Garside1, A Round, K Dalziel, K Stein, P Royle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12633529     DOI： 10.3310/hta6330

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN： 1366-5278            Impact factor:   4.014


× No keyword cloud information.
  3 in total

Review 1.  Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy.

Authors:  Anthony J Hatswell; Nick Freemantle; Gianluca Baio
Journal:  Pharmacoeconomics       Date:  2017-02       Impact factor: 4.981

2.  Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.

Authors:  Kim Dalziel; Ali Round; Ruth Garside; Ken Stein
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Two different point mutations in ABL gene ATP-binding domain conferring Primary Imatinib resistance in a Chronic Myeloid Leukemia (CML) patient: A case report.

Authors:  Zafar Iqbal; Rubina T. Siddiqui; Javed A. Qureshi
Journal:  Biol Proced Online       Date:  2004-07-01       Impact factor: 3.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.